Indicated for: hematologic malignancies
Route of administration: infusion
Substance: decitabine (antimetabolite antineoplastic)
ATC: L01BC08 (Antineoplastic and immunomodulating agents | Antimetabolites | Pyrimidine analogues)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Decitabine is a hypomethylating agent used for the treatment of myelodysplastic syndromes and acute myeloid leukemia. It works by inhibiting DNA methyltransferase, leading to the reactivation of tumor suppressor genes and inhibition of cancer cell growth.
The medication is administered via intravenous infusion, usually in treatment cycles, with the dose adjusted based on the patient's condition and response to therapy. Common side effects include nausea, anemia, neutropenia, and thrombocytopenia.
Decitabine is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. Its use also requires careful monitoring to prevent severe hematological complications.
This medication is an important option for patients with malignant hematological disorders, helping to improve their prognosis.